RM Lago, PP Singh, RW Nesto - The Lancet, 2007 - Elsevier 360 of 20 191 patients who had either prediabetes or type 2 diabetes had congestive heart failure
events (214 with TZDs and 146 with comparators). Results showed no heterogeneity of effects across
studies (I 2 =22·8%; p for ... Cited by 181 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org S Singh, YK Loke, CD Furberg - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—A random-effects meta-analysis of three randomized controlled trials showed an odds ratio
(OR) of 2.1 (95% CI 1.08–4.08; P = 0.03) for the risk of heart failure in patients randomized to
TZDs compared with placebo. Four ... Cited by 65 - Related articles - BL Direct - All 10 versions
FA Masoudi, SE Inzucchi - The American Journal of Cardiology, 2007 - Elsevier Several studies have established a strong and independent relation between diabetes and the risk for
HF. Early data from the Framingham cohort suggested an association between diabetes and the risk for
incident HF independent of ... Cited by 31 - Related articles - All 28 versions
- ►onlinejacc.org WHW Tang, GS Francis - Journal of the American College of Cardiology, 2006 - Elsevier Although it has been customary to highlight the results of pivotal clinical trials in this review,
the year 2006 is best characterized as a year of consensus building in heart failure. Guidelines
from several major cardiology ... Cited by 21 - Related articles - BL Direct - All 45 versions
SE Inzucchi, DK McGuire - Circulation, 2008 - Am Heart Assoc This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their
cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting
emerging data concerning their ... Cited by 22 - Related articles - All 6 versions
ZT Bloomgarden - Diabetes Care, 2006 - Am Diabetes Assoc Pamela Goodwin (Toronto, Canada) introduced the topic of insulin resistance and malignancy, pointing
out that there is variation in cancer incidence around the world, with variations in diet and
obesity as important determining ... Cited by 20 - Related articles - All 10 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y Palacios, … - Journal of Clinical …, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by thiazolidinediones
(pioglitazone, rosiglitazone) and dual-acting PPAR / agonists (pargluva, ragaglitazar) is a widely
used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
ZT Bloomgarden - Diabetes Care, 2007 - Am Diabetes Assoc Perspectives on the News commentaries are now part of a new, free monthly CME activity. The Mount
Sinai School of Medicine, New York, New York, is designating this activity for 2.0 AMA PRA Category
1 credits. If you wish to ... Cited by 18 - Related articles - BL Direct - All 7 versions
BE Sobel - The American Journal of Medicine, 2007 - Elsevier This article presents a series of take-home statements, compiled by a multidisciplinary steering
committee, concerning significant aspects of macrovascular disease in patients with diabetes
mellitus, including the extent of ... Cited by 14 - Related articles - All 12 versions
J Karalliedde, RE Buckingham - Drug Safety, 2007 - ingentaconnect.com Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the Abstract treatment
of type 2 diabetes mellitus. These drugs have a multitude of therapeutic effects including reduction
in insulin resistance and ... Cited by 15 - Related articles - BL Direct - All 6 versions
